EV Biologics Updates on NFT Warrant Dividend Distribution
EV Biologics Updates on NFT Warrant Dividend Distribution
NASHVILLE, TN / ACCESSWIRE / August 30, 2021 / EV Biologics Corp, (OTC Pink:YECO), today updated shareholders with further details about its NFT Warrant Dividend distribution.
田纳西州纳什维尔/ACCESSWIRE/2021年8月30日/EV Biologics Corp(场外交易粉色代码：YECO)今天向股东通报了有关其NFT认股权证股息分配的进一步细节。
The Company is currently finalizing its filing with FINRA, and then will have its transfer agent issue the dividend Warrant through DTC. As previously announced, YECO's shareholders-of-record on July 30, 2021, will receive a Warrant to exercise their right to accept ownership of the NFT.
该公司目前正在最后敲定向FINRA提交的文件，然后将让其转让代理通过DTC发行红利认股权证。正如之前宣布的那样，2021年7月30日，YECO登记在册的股东将收到认股权证，以行使他们接受NFT所有权的权利。
The Company will distribute one (1) Warrant for every 100 shares of YECO common stock held. Each Warrant will be exercisable for one (1) NFT worth $300. Shareholders will have until (December 1, 2021) to exercise their Warrant(s) to receive their NFT(s). Shareholders possessing less than 100 shares will not be eligible for this special dividend.
本公司将为持有的每100股YECO普通股派发一(1)份认股权证。每份认股权证可行使一(1)新台币，价值300美元。股东将在2021年12月1日之前行使他们的认股权证，以获得他们的NFT。持股少于100股的股东将没有资格获得这一特别股息。
The Company will confirm when the Warrant is distributed.
本公司将确认认股权证何时分发。
About the Company
关于本公司
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on developing and enhancing the intrinsic therapeutic activity of mesenchymal stromal cell (MSC) secreted factors, as well as targeted delivery of bioactive molecules using engineered exosomes. The company is working to optimize cell lines for production of native bioactive nanoparticles and to establish an exosome engineering platform to enhance specific therapeutic activity. Initially, these novel regenerative products will be produced for preclinical research on a number of clinical indications. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in these bioengineered products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
EV Biologics(前身为玉龙生态材料有限公司)是一家总部位于美国怀俄明州的生物技术公司，致力于开发和增强间充质基质细胞(MSC)分泌因子的内在治疗活性，并利用工程外泌体靶向输送生物活性分子。该公司正在努力优化细胞系，以生产天然生物活性纳米颗粒，并建立一个外体工程平台，以增强特定的治疗活性。最初，这些新的再生产品将用于一些临床适应症的临床前研究。利用专有和专利技术，该公司正在创造这些生物工程产品固有的独家知识产权和信息技术。进一步的产品开发将集中在针对特定临床条件设计的新型干细胞衍生生物药物的研究上。
Forward-Looking Statements
前瞻性陈述
This news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
本新闻稿包含前瞻性陈述，特别是与公司业务计划有关的陈述，以及与公司财务状况和业务战略有关的目标、计划和预测的陈述。“计划”、“将是”、“将允许”、“打算”、“可能结果”、“预计将”、“将继续”、“预期”、“预期”、“估计”、“项目”、“表明”、“可能”、“可能”、“应该”、“相信”、“思考”、“考虑”或类似的表述旨在识别“前瞻性陈述”。这些前瞻性陈述符合1933年“证券法”第27A节和1934年“证券法”第21E节的含义，并受这两节所创造的安全港的约束。由于一些风险和不确定因素，实际结果可能与前瞻性陈述中预测的结果大不相同。此类前瞻性表述基于当前预期，涉及已知和未知风险、对第三方信息的依赖程度、可能被取消的交易或订单，以及其他可能导致我们的实际结果、业绩或成就或行业发展与此类前瞻性表述明示或暗示的预期结果、业绩或成就大不相同的因素。可能导致实际结果与预期结果大相径庭的因素包括与当地、地区和全球经济状况波动有关的风险和不确定性、管理层和员工的表现、我们获得融资的能力、竞争等。, 一般经济状况和其他因素在我们的定期报告和我们不时提交给美国证券交易委员会(Securities And Exchange Commission)的文件中都有详细说明。本文中所作的陈述是截至本新闻稿发布之日的陈述，不应作为后续任何日期的依据，公司明确表示不承担任何义务更新任何前瞻性陈述，以反映该陈述发表之日之后发生的事件、事态发展、意想不到的事件或情况。
YECO has 7.22 million shares issued and outstanding with a float of 1,016,375 shares.
YECO有722万股已发行和流通股，流通股为1,016,375股。
Contact:
联系方式：
Dennis Burns
Investor Relations
Tel (567)237-4132
dburns@nvestrain.com
丹尼斯·伯恩斯投资者关系电话(567)237-4132邮箱：dburns@nvestrain.com
For more information on EV Biologics please visit:
有关EV Biologics的更多信息，请访问：
www.evbiologics.com
Www.evbiologics.com
SOURCE: EV Biologics, Inc.
资料来源：EV Biologics，Inc.
译文内容由第三方软件翻译。